Skip to main content

Table 1 Patient characteristics

From: Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer

 

AP group

EP group

Number of patients

149

150

Sex

  

 Male

114 (76.5 %)

113 (75.3 %)

 Female

35 (23.5 %)

37 (24.7 %)

Median age, years (SD)a

58.0 (13.0)

59.0 (13.0)

ECOG PS

  

 0

42 (28.2 %)

32 (21.3 %)

 1

107 (71.8 %)

118 (78.7 %)

Stage

  

 IIIB

3 (2.0 %)

9 (6.0 %)

 IV

146 (98.0 %)

141 (94.0 %)

Metastasisb

148 (99.3 %)

144(96.0 %)

 Lung

18 (12.1 %)

22 (14.7 %)

 Bone

60 (40.3 %)

65 (43.3 %)

 Brain

30 (20.1 %)

17 (11.3 %)

 Liver

37 (24.8 %)

41 (27.3 %)

 Other

82 (55.0 %)

78 (52.0 %)

  1. Data are number (%) except amedian (SD)
  2. bSeveral patients had metastases to multiple sites
  3. AP amrubicin/cisplatin, EP etoposide/cisplatin, SD standard deviation, ECOG PS Eastern Cooperative Oncology Group